Goldenwell Biotech, Inc.
GWLL
$0.70
-$0.07-9.09%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.18% | 226.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.18% | -83.02% | |||
| Operating Income | -11.18% | 87.32% | |||
| Income Before Tax | -109.66% | 92.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -109.66% | 92.93% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -109.66% | 92.93% | |||
| EBIT | -11.18% | 87.32% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -100.00% | 91.30% | |||
| Normalized Basic EPS | 0.00% | 86.67% | |||
| EPS Diluted | -100.00% | 91.30% | |||
| Normalized Diluted EPS | 0.00% | 86.67% | |||
| Average Basic Shares Outstanding | 0.00% | -7.22% | |||
| Average Diluted Shares Outstanding | 0.00% | -7.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||